Cancer Type: Breast

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.



Brief Summary The primary objectives of the Phase 1b part of this study are to evaluate the safety and tolerability of TTI-101 when added to palbociclib and aromatase inhibitor (AI) administered orally to participants with HR-positive HER2-negative palbociclib-resistant breast cancer, and to determine the recommended Phase 2 dose (RP2D) for TTI-101 when added to palbociclib and AI.


Brief Summary The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.


Brief Summary STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor [Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)].